檢索結果 - Michael Robbins

  • Showing 1 - 19 results of 19
Refine Results
  1. 1
    Repair of DNA studied with a nuclease specific for UV-induced lesions.

    Repair of DNA studied with a nuclease specific for UV-induced lesions. 由 Bernard S. Strauss, T. Searashi, Michael Robbins

    出版 1966
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  2. 2
    Immune Cell Inhibition by SLAMF7 Is Mediated by a Mechanism Requiring Src Kinases, CD45, and SHIP-1 That Is Defective in Multiple Myeloma Cells

    Immune Cell Inhibition by SLAMF7 Is Mediated by a Mechanism Requiring Src Kinases, CD45, and SHIP-1 That Is Defective in Multiple Myeloma Cells 由 Huaijian Guo, Mario‐Ernesto Cruz‐Munoz, Ning Wu, Michael Robbins, André Veillette

    出版 2014
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  3. 3
    Violent and Nonviolent Death Tolls for the Gaza War: New Primary Evidence

    Violent and Nonviolent Death Tolls for the Gaza War: New Primary Evidence 由 Michael Spagat, Jon Pedersen, Khalil Shikaki, Michael Robbins, Eran Bendavid, Håvard Hegre, Deberati Guha-Sapir

    出版 2025
    獲取全文
    Pré-impressão
    加到收藏夾
    Saved in:
  4. 4
    Molecular Indices of Neuronal and Glial Plasticity in the Hippocampal Formation in a Rodent Model of Age-Induced Spatial Learning Impairment

    Molecular Indices of Neuronal and Glial Plasticity in the Hippocampal Formation in a Rodent Model of Age-Induced Spatial Learning Impairment 由 Kimio Sugaya, Michael Chouinard, R. Greene, Michael Robbins, David Personett, Caroline Kent, Michela Gallagher, Michael McKinney

    出版 1996
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  5. 5
    Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways

    Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways 由 Balaji Balasa, Rui Yun, Nicole A. Belmar, Melvin Fox, Debra T. Chao, Michael Robbins, Gary C. Starling, Audie Rice

    出版 2014
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  6. 6
    Assembly and Regulation of the CD40 Receptor Complex in Human B Cells

    Assembly and Regulation of the CD40 Receptor Complex in Human B Cells 由 Michelle Kuhne, Michael Robbins, John Hambor, Matthew F. Mackey, Yoko Kosaka, Toshihide Nishimura, Jason P. Gigley, Randolph J. Noelle, David M. Calderhead

    出版 1997
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  7. 7
    The CD28 and CTLA-4 Receptors Associate with the Serine/Threonine Phosphatase PP2A

    The CD28 and CTLA-4 Receptors Associate with the Serine/Threonine Phosphatase PP2A 由 Ellen Chuang, Timothy S. Fisher, Rodney Morgan, Michael Robbins, James M. Duerr, Matthew G. Vander Heiden, Joseph P. Gardner, John Hambor, Mark J. Neveu, Craig B. Thompson

    出版 2000
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  8. 8
    The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and –independent mechanisms

    The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and –independent mechanisms 由 Tatiana Pazina, Ashley M. James, Alexander W. MacFarlane, Natalie Bezman, Karla A. Henning, Christine Bee, Robert F. Graziano, Michael Robbins, Adam D. Cohen, Kerry S. Campbell

    出版 2017
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  9. 9
    Alterations of NK Cell Phenotype in the Disease Course of Multiple Myeloma

    Alterations of NK Cell Phenotype in the Disease Course of Multiple Myeloma 由 Tatiana Pazina, Alexander W. MacFarlane, Luca Bernabei, Essel Dulaimi, Rebecca E. Kotcher, Clinton Yam, Natalie Bezman, Michael Robbins, Eric A. Ross, Kerry S. Campbell, Adam D. Cohen

    出版 2021
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  10. 10
    Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma

    Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma 由 Tatiana Pazina, Ashley M. James, Kimberly B. Colby, Yibin Yang, Andrew N. Gale, Amy Jhatakia, Alper Y. Kearney, Robert F. Graziano, Natalie Bezman, Michael Robbins, Adam D. Cohen, Kerry S. Campbell

    出版 2019
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  11. 11
    Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened

    Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened 由 Michael J. Munchhof, Qifang Li, Andrei Shavnya, Gary Borzillo, Tracey Boyden, Christopher S. Jones, Susan LaGreca, Luis Martinez-Alsina, Nandini C. Patel, Kathleen Pelletier, Larry A. Reiter, Michael Robbins, George T. Tkalcevic

    出版 2011
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  12. 12
    PD-1 blockade enhances elotuzumab efficacy in mouse tumor models

    PD-1 blockade enhances elotuzumab efficacy in mouse tumor models 由 Natalie Bezman, Amy Jhatakia, Alper Y. Kearney, Ty Brender, Mark Maurer, Karla A. Henning, Misty R. Jenkins, Amy J. Rogers, Paul J. Neeson, Alan J. Korman, Michael Robbins, Robert F. Graziano

    出版 2017
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  13. 13
    Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab

    Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab 由 Ahmed T. Kurdi, Siobhan Glavey, Natalie Bezman, Amy Jhatakia, Jennifer L. Guerriero, Salomon Manier, Michele Moschetta, Yuji Mishima, Aldo M. Roccaro, Alexandre Detappe, Chia‐Jen Liu, Antonio Sacco, Daisy Huynh, Yu‐Tzu Tai, Michael Robbins, Jamil Azzi, Irene M. Ghobrial

    出版 2018
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  14. 14
    Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM

    Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM 由 Andrzej Jakubowiak, Massimo Offidani, Brigitte Pegourié, Javier de la Rubia, Laurent Garderet, Kamel Laribi, Alberto Bosi, Roberto Marasca, Jacob P. Laubach, Ann Mohrbacher, Angelo Michele Carella, Anil Singhal, L. Claire Tsao, Mark Lynch, Eric Bleickardt, Ying‐Ming Jou, Michael Robbins, Antonio Palumbo

    出版 2016
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  15. 15
    Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma

    Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma 由 Meletios Α. Dimopoulos, Dominik Dytfeld, Sebastian Grosicki, Philippe Moreau, Naoki Takezako, Mitsuo Hori, Xavier Leleu, Richard LeBlanc, Kenshi Suzuki, Marc S. Raab, Paul G. Richardson, Mihaela Popa McKiver, Ying-Ming Jou, Suresh G. Shelat, Michael Robbins, Brian T. Rafferty, Jesús F. San Miguel

    出版 2018
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  16. 16
    A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma

    A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma 由 Irene M. Ghobrial, Chia‐Jen Liu, Robert Redd, Raymond P. Perez, Rachid Baz, Oksana Zavidij, Romanos Sklavenitis‐Pistofidis, Paul G. Richardson, Kenneth C. Anderson, Jacob P. Laubach, Patrick Henrick, Alexandra Savell, Kaitlen Reyes, Kalvis Hornburg, Stacey Chuma, Peter Sabbatini, Michael Robbins, Pamela S. Becker

    出版 2019
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  17. 17
    The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications

    The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications 由 Kenneth C. Anderson, Daniel Auclair, Gary J. Kelloff, Caroline C. Sigman, Hervé Avet‐Loiseau, Ann T. Farrell, Nicole Gormley, Shaji Kumar, Ola Landgren, Nikhil C. Munshi, Michèle Cavo, Faith E. Davies, Alessandra Di Bacco, Jennifer S. Dickey, Steven Gutman, Howard R. Higley, Mohamad A. Hussein, J. Milburn Jessup, Ilan R. Kirsch, Richard F. Little, Robert D. Loberg, Jens G. Lohr, Lata Mukundan, James Omel, Trevor J. Pugh, Gregory H. Reaman, Michael Robbins, A. Kate Sasser, Nancy Valente, Elena Zamagni

    出版 2017
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  18. 18
    Clinical Genetic Testing for Patients With Autism Spectrum Disorders

    Clinical Genetic Testing for Patients With Autism Spectrum Disorders 由 Yiping Shen, Kira A. Dies, Ingrid A. Holm, Carolyn Bridgemohan, Magdi M. Sobeih, Elizabeth Caronna, Karen J. Miller, Jean A. Frazier, Iris Silverstein, Jonathan Picker, Laura Weissman, Peter Raffalli, Shafali Jeste, Laurie Demmer, Heather Peters, Stephanie J. Brewster, Sara J. Kowalczyk, Beth Rosen‐Sheidley, Caroline McGowan, Andrew W. Duda, Sharyn A. Lincoln, Kathryn Lowe, Alison Schonwald, Michael Robbins, Fuki M. Hisama, Robert R. Wolff, Ronald E. Becker, Ramzi Nasir, David K. Urion, Jeff M. Milunsky, Leonard Rappaport, James F. Gusella, Christopher A. Walsh, Bai-Lin Wu, David T. Miller

    出版 2010
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  19. 19
    Copy number variation plays an important role in clinical epilepsy

    Copy number variation plays an important role in clinical epilepsy 由 Heather E. Olson, Yiping Shen, Jennifer Avallone, Beth Rosen Sheidley, Rebecca Pinsky, Ann M. Bergin, Gerard T. Berry, Frank H. Duffy, Yaman Z. Ekşioğlu, David J. Harris, Fuki M. Hisama, Eugenia Ho, Mira Irons, Christina M. Jacobsen, Philip James, Sanjeev V. Kothare, Omar Khwaja, Jonathan O. Lipton, Tobias Loddenkemper, Jennifer A. Markowitz, Kiran Maski, J. Thomas Megerian, Edward Neilan, Peter C. Raffalli, Michael Robbins, Amy E. Roberts, Eugene Roe, Caitlin K. Rollins, Mustafa Şahin, Dean Sarco, Alison Schonwald, Sharon E. Smith, Janet S. Soul, Joan M. Stoler, Masanori Takeoka, Wen‐Hann Tan, Alcy Torres, Peter T. Tsai, David K. Urion, Laura Weissman, Robert R. Wolff, Bai‐Lin Wu, David T. Miller, Annapurna Poduri

    出版 2014
    獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: